Akebia Therapeutics Inc [AKBA] stock is trading at $3.93, down -1.26%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AKBA shares have gain 8.56% over the last week, with a monthly amount glided 0.26%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Leerink Partners started tracking the stock with Outperform rating on April 28, 2025, and set its price target to $7. On April 01, 2025, Jefferies initiated with a Buy rating and assigned a price target of $6 on the stock. H.C. Wainwright upgraded its rating to a Buy but $3.75 remained the price target by the analyst firm on August 28, 2023. Piper Sandler upgraded its rating to Overweight for this stock on May 31, 2023, and upped its price target to $4. In a note dated March 31, 2022, Piper Sandler downgraded an Neutral rating on this stock and revised its target price from $8 to $2.
Akebia Therapeutics Inc [AKBA] stock has fluctuated between $1.07 and $4.08 over the past year. Currently, Wall Street analysts expect the stock to reach $6.5 within the next 12 months. Akebia Therapeutics Inc [NASDAQ: AKBA] shares were valued at $3.93 at the most recent close of the market. An investor can expect a potential return of 65.39% based on the average AKBA price forecast.
Analyzing the AKBA fundamentals
Akebia Therapeutics Inc [NASDAQ:AKBA] reported sales of 184.91M for the trailing twelve months, which represents a growth of 75.84%. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -0.12%, Pretax Profit Margin comes in at -0.25%, and Net Profit Margin reading is -0.25%. To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is 1.67 and Total Capital is -0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.87 points at the first support level, and at 3.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.04, and for the 2nd resistance point, it is at 4.14.
Ratios To Look Out For
For context, Akebia Therapeutics Inc’s Current Ratio is 2.23. Also, the Quick Ratio is 2.02, while the Cash Ratio stands at 1.24. Considering the valuation of this stock, the price to sales ratio is 5.58, the price to book ratio is 41.83.
Transactions by insiders
Recent insider trading involved Ostrowski Erik, SVP, CFO, CBO & Treasurer, that happened on Jun 30 ’25 when 41314.0 shares were sold. Officer, Ostrowski Erik completed a deal on Jun 30 ’25 to buy 41314.0 shares. Meanwhile, SVP, Chief Accounting Officer Malabre Richard C sold 15000.0 shares on Jun 09 ’25.
